Post navigation Arcturus Therapeutics GAAP EPS of -$2.40 misses by $0.24, revenue of $82M misses by $8.47MAntengene and UCB Enter Global License Agreement for ATG-201, a CD19/CD3 Bispecific T-Cell Engager for Autoimmune Diseases